Skip to content
Company
About
Leadership
Scientific & Clinical Directors
Board Members
Scientific Advisory Board
Technology
Pipeline
Overview
Immuno-Oncology
BND-22
BND-35
BND-67
INspire pipeline
BION-301
BION-302
Clinical Trials
News
Public Relations
Events
Coverage
Publications
Collaborations
Contact Us
Menu
Company
About
Leadership
Scientific & Clinical Directors
Board Members
Scientific Advisory Board
Technology
Pipeline
Overview
Immuno-Oncology
BND-22
BND-35
BND-67
INspire pipeline
BION-301
BION-302
Clinical Trials
News
Public Relations
Events
Coverage
Publications
Collaborations
Contact Us
Company
About
Leadership
Scientific & Clinical Directors
Board Members
Scientific Advisory Board
Technology
Pipeline
Overview
Immuno-Oncology
BND-22
BND-35
BND-67
INspire pipeline
BION-301
BION-302
Clinical Trials
News
Public Relations
Events
Coverage
Publications
Collaborations
Contact Us
Menu
Company
About
Leadership
Scientific & Clinical Directors
Board Members
Scientific Advisory Board
Technology
Pipeline
Overview
Immuno-Oncology
BND-22
BND-35
BND-67
INspire pipeline
BION-301
BION-302
Clinical Trials
News
Public Relations
Events
Coverage
Publications
Collaborations
Contact Us
Public Relations
Biond Biologics Announces Presentation of BND-35, a Novel Anti-ILT3 Antibody for Remodeling the Tumor Microenvironment, at the American Association for Cancer Research (AACR) 2024 Annual Meeting
March 26, 2024
Biond Biologics Announces a Joint Research Publication With Sanofi in the Journal for ImmunoTherapy of Cancer, "BND-22, a First-In-Class Humanized ILT2-Blocking Antibody, Promotes Antitumor Immunity and Tumor Regression"
September 14, 2022
Biond Biologics Announces a Joint Poster Presentation With Sanofi at The ASCO 2022 Annual Meeting Presenting Pre-Clinical Translational Data of SAR444881 (BND-22)
May 31, 2022
Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial
May 23, 2022
Biond Biologics Announces Oral Presentation for BND-67, an Inhibitor of CD28 Shedding, a Potential Novel Resistance Mechanism to Anti PD-1 Therapy, at the American Association for Cancer Research (AACR) 2022 Annual Meeting
March 21, 2022
Biond Biologics Announces Closing of $15 Million Series C Financing
November 3, 2021
Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
April 26, 2021
Biond Biologics Announces Global Licensing Agreement with Sanofi for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
January 12, 2021
Biond Biologics Announces Poster Presentations at AACR 2020 Virtual Annual Meeting
June 9, 2020
Biond Biologics Appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate Update
June 1, 2020
Biond Biologics Appoints Immunotherapy Pioneer Alan Korman Ph.D. to Scientific Advisory Board
November 25, 2019
Biond Biologics Annual Company Gathering | Misgav Industrial Park
May 12, 2019
Biond Biologics Announces $17 Million Financing
January 8, 2019